spacer
home > epc > Autumn 2013
PUBLICATIONS

European Pharmaceutical Contractor

epc
Autumn 2013

   
Text
PDF
bullet
Keynote
Editor’s Letter

Graham Hughes picks up on the theme of risk that runs through many articles in this edition, from informing patients about drug safety, to protecting business operations.
 
view
download pdf
bullet
Marketplace & Business
Academic Research Organisations

Lighting the Way

Academic bodies are making a big comeback, challenging contract research organisations in the global trials marketplace. Cyrus Park at Julius Clinical charts their history and addresses some misperceptions over their role.
 
view
download pdf

Business Performance

Battle Ready

Emerging markets are a critical battleground for pharma companies seeking to rejuvenate their R&D business. But is it better to partner with global or local contract research organisations? Igor Stefanov at Synergy Research Group investigates.

 
view
download pdf
Anti-Counterfeiting

False Move

In the ongoing war against fake drugs, legal moves worldwide tend to focus on digital traceability. Mark Davison at Blue Sphere Health emphasises that manufacturers should also consider physical security and processes as part of an integrated strategy.
 
view
download pdf
bullet
Legal & Regulatory
Regulatory Affairs

Legal Studies


Regulatory affairs professionals have a critical role in speeding up approvals, reducing risk and improving the efficiency of multiple processes along the product lifecycle. Preeya Beczek at Pharm-Olam International looks at the skills they need.


 
view
download pdf
Drug Safety

Worth the Risk?

The industry hasn’t got the best record when it comes to giving patients sufficient risk information about the safety of medicines. Lisa Bolitho and Mark NelsonTyrrell at ICON Clinical Research explain how regulatory developments aim for a more proactive approach.
 
view
download pdf
Falsified Medicines

Keeping it Real

This summer sees tougher rules on active substances imported into Europe come into force as part of the Falsified Medicines Directive. Michael Finn and Paul Clifford at Matheson look at the implications for those in the supply chain and how they can comply.
 
view
bullet
India Focus

In Conclusion

Trying Times

There is divided opinion over India as a suitable destination for clinical trials: advocates point to new and improved regulations, but many remain disillusioned, says Graham Hughes.

 
view
download pdf
bullet
Science & Innovation
Dosage Forms

Putting the Fizz into Formulation

From ease of swallowing through to simplifed treatment regimens, effervescent tablets and granules provide numerous patient benefi ts. Not suprisingly, a large market exists for their innovative manufacture and development, as Detlev Haack and Martin Köberle at Hermes Pharma explain.
 
view
download pdf
Oncology R&D

Shared Vision

Using imaging-based surrogate endpoints as biomarkers can speed up trials, underline safety and efficacy, and support clinical data for decision-making and regulatory submission, says Oliver Bohnsack at Perceptive Informatics
 
view
download pdf
bullet
Therapeutic Innovation

Personalised Medicine

Next Generation

Circulating tumour cell diagnostic tests have only recently become mainstream but now look set to push a new era of targeted therapeutics in oncology – with China positioning itself to take commercial advantage. Ken Pennline at LabCorp Clinical Trials reports.

 
view
download pdf
bullet
Risk Management

Risk Management

Healthcare Ecosystem

Expanded boundaries, new technology and end-to-end solutions offer tremendous benefits, but also bring growing complexity and risk that life sciences companies must manage.Heather Fraser at IBM discusses the issues.

 
view
download pdf

Research and Development
Pharma Marketing

Picture This

Pharmaceutical and healthcare brands are tapping into the growing consumer trend which interconnects health and happiness by using imagery to communicate with customers and inspire trust. Michaela Schwing at Getty Images reports.

 
view
download pdf

Interview
Q&A: Patient Engagement

Personal Development

Warning that the current healthcare model is unsustainable, Judith Teall at Exco InTouch examines the industry’s evolution towards personal technologies for patient recruitment and engagement in clinical research.
 
view
download pdf
Interview: Aurélien Dupuy

Industry Forecast

GlobalData’s Director for Oncology, Haematology and Gender Health outlines his career path and argues that the industry – and particularly small pharma – is reaching a critical point.
 
view
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

Avacta and Mologic Enter Research and Product Development Collaboration Agreement

Avacta announces the formation of a collaborative research partnership
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement